353 related articles for article (PubMed ID: 34050566)
21. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor S; Petit I
Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
[TBL] [Abstract][Full Text] [Related]
22. Stromal-derived factor-1 deficiency in the bone marrow of acute myeloid leukemia.
Ge J; Hou R; Liu Q; Zhu R; Liu K
Int J Hematol; 2011 Jun; 93(6):750-759. PubMed ID: 21607655
[TBL] [Abstract][Full Text] [Related]
23. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow mesenchymal stem cells in microenvironment transform into cancer-associated fibroblasts to promote the progression of B-cell acute lymphoblastic leukemia.
Pan C; Liu P; Ma D; Zhang S; Ni M; Fang Q; Wang J
Biomed Pharmacother; 2020 Oct; 130():110610. PubMed ID: 34321159
[TBL] [Abstract][Full Text] [Related]
25. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C
Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351
[TBL] [Abstract][Full Text] [Related]
26. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
27. Dextran sulfate and stromal cell derived factor-1 promote CXCR4 expression and improve bone marrow homing efficiency of infused hematopoietic stem cells.
Hayakawa J; Migita M; Ueda T; Fukazawa R; Adachi K; Ooue Y; Hayakawa M; Shimada T; Fukunaga Y
J Nippon Med Sch; 2009 Aug; 76(4):198-208. PubMed ID: 19755795
[TBL] [Abstract][Full Text] [Related]
28. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy-induced alteration of SDF-1/CXCR4 expression in bone marrow-derived mesenchymal stem cells from adolescents and young adults with acute lymphoblastic leukemia.
Ge J; Hu Y; Gui Y; Hou R; Yang M; Zeng Q; Xia R
J Pediatr Hematol Oncol; 2014 Nov; 36(8):617-23. PubMed ID: 25072364
[TBL] [Abstract][Full Text] [Related]
30. Stromal-derived factor-1/CXCR4 signaling: indispensable role in homing and engraftment of hematopoietic stem cells in bone marrow.
Sharma M; Afrin F; Satija N; Tripathi RP; Gangenahalli GU
Stem Cells Dev; 2011 Jun; 20(6):933-46. PubMed ID: 21186999
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
Jonart LM; Ostergaard J; Brooks A; Fitzpatrick G; Chen L; Gordon PM
Br J Haematol; 2023 May; 201(3):459-469. PubMed ID: 36535585
[TBL] [Abstract][Full Text] [Related]
32. CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK.
Juarez JG; Thien M; Dela Pena A; Baraz R; Bradstock KF; Bendall LJ
Br J Haematol; 2009 May; 145(4):491-9. PubMed ID: 19344405
[TBL] [Abstract][Full Text] [Related]
33. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
Burger JA; Kipps TJ
Blood; 2006 Mar; 107(5):1761-7. PubMed ID: 16269611
[TBL] [Abstract][Full Text] [Related]
34. CXCR4 (CD184) expression on stem cell harvest and CD34
Asfour I; Afify H; Elkourashy S; Ayoub M; Kamal G; Gamal M; Elgohary G
Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):63-69. PubMed ID: 28282510
[TBL] [Abstract][Full Text] [Related]
35. [Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration].
Liu ZR; Sun H; Zou P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):1-5. PubMed ID: 16584580
[TBL] [Abstract][Full Text] [Related]
36. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
Cho BS; Kim HJ; Konopleva M
Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
[TBL] [Abstract][Full Text] [Related]
37. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
Sison EA; Rau RE; McIntyre E; Li L; Small D; Brown P
Br J Haematol; 2013 Mar; 160(6):785-97. PubMed ID: 23294096
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia.
Crazzolara R; Jöhrer K; Johnstone RW; Greil R; Kofler R; Meister B; Bernhard D
Br J Haematol; 2002 Dec; 119(4):965-9. PubMed ID: 12472574
[TBL] [Abstract][Full Text] [Related]
39. A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells.
Broussas M; Boute N; Akla B; Berger S; Beau-Larvor C; Champion T; Robert A; Beck A; Haeuw JF; Goetsch L; Bailly C; Dumontet C; Matthes T; Corvaia N; Klinguer-Hamour C
Mol Cancer Ther; 2016 Aug; 15(8):1890-9. PubMed ID: 27297868
[TBL] [Abstract][Full Text] [Related]
40. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
